This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Pediatrics  • Adolescent Medicine  • Tobacco  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Commentary by Suzanne M. Colby, PhD; Chad J. Gwaltney, PhD

JAMA. 2007;298(18):2182-2184.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE

Randomized, Double-blind, Placebo-Controlled Trial of 2 Dosages of Sustained-Release Bupropion for Adolescent Smoking Cessation

Myra L. Muramoto, MD, MPH; Scott J. Leischow, PhD; Duane Sherrill, PhD; Eva Matthews, MPH; Louise J. Strayer, BSc, RN, MSc

Objective: To assess the safety and efficacy of sustained-release bupropion hydrochloride for adolescent smoking cessation.

Design: Prospective, randomized, double-blind, placebo-controlled, dose-ranging trial.

Setting: Metropolitan areas of Tucson and Phoenix, Arizona.

Participants: Adolescents (N = 312) recruited through media and various community venues from March 1, 1999, through December 31, 2002, who were aged 14 to 17 years, smoked 6 or more cigarettes per day, had an exhaled carbon monoxide level of 10 ppm or greater, had at least 2 previous quit attempts, and had no other current major psychiatric diagnosis.

Intervention: Sustained-release bupropion hydrochloride, 150 mg/d (n = 105) or 300 mg/d (n = 104), . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Smoking cessation pharmacotherapy
Frishman
Ther Adv Cardiovasc Dis 2009;3:287-308.
ABSTRACT